Grifols S.A.

Grifols, based near Barcelona and family-controlled, is one of the world's largest makers of plasma-derived medicines, collecting blood plasma at hundreds of donor centres and turning it into treatments for immune disorders and other conditions. Essential, hard-to-replicate products give it a strong market position, but a heavy debt load and governance concerns have shaken investor confidence. Grifols suspended its ordinary dividend to conserve cash and cut debt, so income plays no part in the case for now, which leaves its score low. This is a turnaround story tied to reducing debt and restoring trust rather than a dividend stock.